Correction
27 July 2007
Reply:
Arun Sanyal, Nisha Chand – 27 July 2007
Sepsis‐induced cholestasis
Kurt Lenz, Christine Kapral, Fritz Firlinger, Fritz Wewalka – 27 July 2007
Randomized trial of interferon beta‐1a with or without ribavirin in Asian patients with chronic hepatitis C
Henry L. Y. Chan, Hong Ren, Wan C. Chow, Theodore Wee, Interferon beta‐1a Hepatitis C Study Group – 27 July 2007 – The standard of care for chronic hepatitis C virus (HCV) infection, pegylated interferon (IFN) alpha plus ribavirin, results in a sustained virologic response (SVR) in approximately 50%‐60% of patients. IFN beta is a potential alternative to IFN alpha. The aim of this study was to investigate the efficiency and durability of IFN beta and its combination with ribavirin in the naïve setting of chronic hepatitis C in Asian patients.
Natural history and disease progression in Chinese chronic hepatitis B patients in immune‐tolerant phase
Chee‐Kin Hui, Nancy Leung, Siu‐Tsan Yuen, Hai‐Ying Zhang, Kar‐Wai Leung, Lei Lu, Stephen K. F. Cheung, Wai‐Man Wong, George K. Lau, Hong Kong Liver Fibrosis Study Group – 27 July 2007 – In view of the findings that high hepatitis B virus (HBV) deoxyribonucleic acid (DNA) is associated with increased risk of chronic hepatitis B (CHB)–related complications, disease progression in CHB patients in the immune‐tolerant phase is uncertain. We evaluated disease progression in 57 immune‐tolerant CHB patients with high HBV DNA. Each subject underwent an initial liver biopsy.
Is vitamin E beneficial in chronic liver disease?
Ingrid Hickman, Graeme Macdonald – 27 July 2007
The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis
Stephen H. Caldwell, James T. Patrie, Elizabeth M. Brunt, Jan A. Redick, Christine A. Davis, Sang H. Park, Brent A. Neuschwander‐Tetri – 27 July 2007 – Rosiglitazone, a thiazolidinedione peroxisome proliferator‐activated receptor gamma ligand, reduces disease activity in nonalcoholic steatohepatitis (NASH), a disease associated with hepatocyte mitochondrial crystalline inclusions that are not seen in animal models of NASH. In human and animal studies of adipose tissue, thiazolidinediones may induce mitochondrial biogenesis and associated morphological changes.
Increasing the mutation rate for jagged1 mutations in patients with Alagille syndrome
David L. Suskind, Karen F. Murray – 27 July 2007
Divergent effects of peroxisome proliferator–activated receptor‐γ ligands in human and mouse nonalcoholic steatohepatitis
Stephen H. Caldwell, Curtis K. Argo – 27 July 2007
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis
Glen Lutchman, Apurva Modi, David E. Kleiner, Kittichai Promrat, Theo Heller, Marc Ghany, Brian Borg, Rohit Loomba, T. Jake Liang, Ahalya Premkumar, Jay H. Hoofnagle – 27 July 2007 – A pilot study of a 48‐week course of pioglitazone demonstrated significant improvements in the biochemical and histological features of nonalcoholic steatohepatitis (NASH). The aim of the study was to assess the effects of stopping pioglitazone. Twenty‐one patients with NASH were treated with pioglitazone (30 mg/day) for 48 weeks and underwent baseline and end‐of‐treatment evaluation including liver biopsy.